These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 9835540)

  • 1. Comparative efficacy of trovafloxacin in experimental endocarditis caused by ciprofloxacin-sensitive, methicillin-resistant Staphylococcus aureus.
    Kim YS; Liu Q; Chow LL; Chambers HF; Täuber MG
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3325-7. PubMed ID: 9835540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of trovafloxacin in treatment of experimental staphylococcal or streptococcal endocarditis.
    Entenza JM; Vouillamoz J; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 1999 Jan; 43(1):77-84. PubMed ID: 9869569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to trovafloxacin.
    Bonilla HF; Zarins LT; Bradley SF; Kauffman CA
    Diagn Microbiol Infect Dis; 1996 Sep; 26(1):17-21. PubMed ID: 8950524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CI-960, a new fluoroquinolone, for therapy of experimental ciprofloxacin-susceptible and -resistant Staphylococcus aureus endocarditis.
    Kaatz GW; Seo SM; Lamp KC; Bailey EM; Rybak MJ
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1192-7. PubMed ID: 1329613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections.
    Endtz HP; Mouton JW; den Hollander JG; van den Braak N; Verbrugh HA
    Antimicrob Agents Chemother; 1997 May; 41(5):1146-9. PubMed ID: 9145886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection of fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus with ciprofloxacin and trovafloxacin.
    Evans ME; Titlow WB
    Antimicrob Agents Chemother; 1998 Mar; 42(3):727. PubMed ID: 9517965
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy of trovafloxacin against experimental Staphylococcus aureus endocarditis.
    Kaatz GW; Seo SM; Aeschlimann JR; Houlihan HH; Mercier RC; Rybak MJ
    Antimicrob Agents Chemother; 1998 Feb; 42(2):254-6. PubMed ID: 9527768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response of complicated methicillin-resistant Staphylococcus aureus endocarditis to the addition of trovafloxacin.
    Eckart RE; Hospenthal DR; Fishbain JT
    Pharmacotherapy; 2000 May; 20(5):589-92. PubMed ID: 10809347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of levofloxacin for experimental aortic-valve endocarditis in rabbits infected with viridans group streptococcus or Staphylococcus aureus.
    Chambers HF; Xiang Q; Liu ; Chow LL; Hackbarth C
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2742-6. PubMed ID: 10543757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activities of trovafloxacin and ampicillin-sulbactam alone or in combination versus three strains of vancomycin- intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model.
    Aeschlimann JR; Hershberger E; Rybak MJ
    Antimicrob Agents Chemother; 2000 May; 44(5):1153-8. PubMed ID: 10770744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus.
    Entenza JM; Vouillamoz J; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 1997 Aug; 41(8):1662-7. PubMed ID: 9257737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of experimental staphylococcal endocarditis due to a strain with reduced susceptibility in vitro to vancomycin: efficacy of ampicillin-sulbactam.
    Backo M; Gaenger E; Burkart A; Chai YL; Bayer AS
    Antimicrob Agents Chemother; 1999 Oct; 43(10):2565-8. PubMed ID: 10508047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ampicillin, sulbactam, and rifampin combination treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis in rabbits.
    Chambers HF; Kartalija M; Sande M
    J Infect Dis; 1995 Apr; 171(4):897-902. PubMed ID: 7706817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.
    Entenza JM; Que YA; Vouillamoz J; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3076-83. PubMed ID: 11600359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topoisomerase mutations in trovafloxacin-resistant Staphylococcus aureus.
    Fitzgibbon JE; John JF; Delucia JL; Dubin DT
    Antimicrob Agents Chemother; 1998 Aug; 42(8):2122-4. PubMed ID: 9687420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Y-688, a new quinolone active against quinolone-resistant Staphylococcus aureus: lack of in vivo efficacy in experimental endocarditis.
    Entenza JM; Marchetti O; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 1998 Aug; 42(8):1889-94. PubMed ID: 9687379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of fleroxacin in experimental methicillin-resistant Staphylococcus aureus endocarditis.
    Kaatz GW; Seo SM; Barriere SL; Albrecht LM; Rybak MJ
    Antimicrob Agents Chemother; 1989 Apr; 33(4):519-21. PubMed ID: 2499251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model.
    Firsov AA; Vostrov SN; Kononenko OV; Zinner SH; Portnoy YA
    Antimicrob Agents Chemother; 1999 Mar; 43(3):498-502. PubMed ID: 10049257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.
    Madrigal AG; Basuino L; Chambers HF
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3163-5. PubMed ID: 16048918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of the combination of trovafloxacin and other antibiotics against enterococci.
    Schick DG; Canawati HN; Montgomerie JZ
    Diagn Microbiol Infect Dis; 1997 Dec; 29(4):233-9. PubMed ID: 9458980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.